The Technical Analyst
Defiance Nasdaq Junior [IBBJ]
Exchange: NASDAQ Global Market
Defiance Nasdaq Junior Price, Forecast, Insider, Ratings, Fundamentals & Signals
-0.07% $29.87
/ 2 des 2021 @ 16:00
| FUNDAMENTALS | |
|---|---|
| MarketCap: | 8.23 mill |
| EPS: | 0 |
| P/E: | 0 |
| Earnings Date: | N/A |
| SharesOutstanding: | 0.275 mill |
| Avg Daily Volume: | 0.0024 mill |
| PE RATIO: COMPANY / SECTOR |
|---|
| 0.00x |
| Company: PE 0 | sector: PE 0 |
| PE RATIO: COMPANY / INDUSTRY |
|---|
| N/A |
| Company: PE 0 | industry: PE 0 |
| DISCOUNTED CASH FLOW VALUE |
|---|
| N/A |
| N/A |
| Expected Trading Range (DAY) |
|---|
|
$ 29.58 - 30.16 ( +/- 0.96%) |
| ATR Model: 14 days |
Forecast:
01:40 - $29.41
Live Trading Signals (every 1 min)
SCORE
10.00
Buy
10.00
Buy
Score Algorithm Version: 1.2C
Last version updated: Fri April 15th, 2022
Last version updated: Fri April 15th, 2022
| Indicator Signals | |
|---|---|
| RSI 21 | |
| SMA | |
| Trend | |
| Trend 2 | |
| Trend 3 | |
| MACD |
| Volume Signals | |
|---|---|
| Price | $29.87 (-0.07% ) |
| Volume | 0.0022 mill |
| Avg. Vol. | 0.0024 mill |
| % of Avg. Vol | 90.03 % |
| Signal 1: | |
| Signal 2: |
Today
Last 12 Months
RSI
Last 10 Buy & Sell Signals For IBBJ
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
| Date | Signal | @ | Closed | % |
|---|
IBBJ
The investment seeks to track the total return performance, before fees and expenses, of the NASDAQ Junior Biotechnology Index. The index is a rules-based index that consists of a portfolio of the stock of U.S.-listed small capitalization ("junior") companies screened from the universe of the NASDAQ Biotechnology Index. The fund will generally use a "replication" strategy to achieve its investment objective, meaning it will generally invest in all of the component securities of the index in the same approximate proportions as in the index. The fund is non-diversified.
Latest Press Releases
2020-11-12 15:36:00 - Press Release
Ibbj Etf, The Junior Biotech Etf Outperforming Nasdaq Biotechnology Index
New york--(business wire)---- $ibbj #biotech--about defiance: founded in 2018, defiance etfs is an exchange-traded funds (etfs) sponsor and registered investment advisor, focused on thematic investing. defiance's organic growth, driven by our innovative first-mover etfs and cutting-edge digital footprint, has made defiance into one of the most dynamic investment brands. our suite of rules-based etfs allows retail investors, financial advisors and institutions to express a targeted view on subsectors that are lead
Latest News
2021-12-07 10:23:36 - ETFcom
ETF Odds & Ends: Closures Accelerate
2021-10-30 01:20:42 - ETFcom
ETF Odds & Ends: Launches Resurge
2021-09-09 15:46:36 - ETF Trends
Biotech ETFs Benefit From Moderna Dual Booster Shot News
As the stock market attempts to reverse the recent pullback this month, Moderna shares climbed higher on Thursday after the company announced that it's creating a dual-purpose vaccine booster shot that offers protection against both the coronavirus and the seasonal flu. The new vaccine booster, which the biotech company calls mRNA-1073, combines Moderna's current coronavirus vaccine [.
2021-08-24 12:59:24 - Zacks Investment Research
Healthcare ETFs Surge on FDA Full-Vaccine Nod & Deal News
The FDA granted full approval of a COVID-19 vaccine made by Pfizer (PFE) and BioNTech that could accelerate inoculations in the United States.
2021-08-19 14:43:36 - ETF Trends
Bet on Biotech Small Caps to Bounce Back
Large cap biotechnology have strengthened in recent months, but smaller counterparts are still waiting on their 2021 moment. When that happens, the Defiance Nasdaq Junior Biotechnology ETF (IBBJ) could be the ETF to watch.
2021-06-24 10:01:17 - InvestorPlace
7 Stocks to Buy Now if You're Feeling Greedy While Others Are Fearful
Stock markets run on fear and greed in the short term. Here are seven stocks to buy that look like they have significant long-term upside.
2021-04-16 11:10:18 - Seeking Alpha
Biotech Innovations Remain At Forefront
The first quarter of 2021 was challenging for the biotechnology industry, as the selloff in March represented a sharp reversal from record highs in February. While the sector has remained relatively resilient throughout the pandemic, we expect a full recovery in the latter half of this year, as operations that were disrupted return to normal.
2021-04-15 09:31:55 - Seeking Alpha
Moving Beyond COVID In Biopharma
Just over one year after COVID-19 disrupted our lives, we are now getting to the point where multiple vaccine options are nearly ubiquitous for those in the United States. Per the CDC, as of April 12, 36% of the entire US population has received at least one vaccine, and 79% of those aged 65 years and older.
2021-03-29 04:23:00 - Seeking Alpha
Defiance ETFs: A Revolution In Thematic ETF Investing (Podcast Transcript)
2021-03-26 09:35:39 - ETF Trends
Why Small Cap Biotech ETFs Are Still Brilliant Bets
